Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**RGC-COV19** is an investigational, orally administered liquid formula developed by Regencell Bioscience using natural ingredients based on Traditional Chinese Medicine (TCM) principles. It is designed to treat mild to moderate COVID-19 symptoms by stimulating the body's own healing mechanisms, specifically to reduce and clear mucus and phlegm from the upper respiratory system, dispel exterior viral pathogens via heavy sweats, urine, and excrement, clear endogenous and liver heat, detoxify the liver, and improve body circulation. In the EARTH efficacy trial involving 37 patients, 97.3% had symptoms eliminated within a 6-day treatment period (except sensory dysfunction and occasional cough), with 83.8% reporting elimination of one or more symptoms after one full dose; no adverse events, hospitalizations, or deaths were reported, and efficacy was consistent across demographics, vaccination status, and comorbidities.[1][2][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RGC-COV19.